Cogent Biosciences
COGT
48 hedge funds and large institutions have $158M invested in Cogent Biosciences in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
9% more funds holding
Funds holding: 44 → 48 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.07% less ownership
Funds ownership: 12.88% → 12.82% (-0.07%)
26% less capital invested
Capital invested by funds: $212M → $158M (-$54.5M)
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$989K |
| 2 |
CI
Cowen Inc
New York
|
+$970K |
| 3 |
D.E. Shaw & Co
New York
|
+$720K |
| 4 |
State Street
Boston,
Massachusetts
|
+$630K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$434K |
Top Sellers
COGT Hedge Fund Activity: Q3 2018 in Review
48 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2018, worth a combined $158M — down 26% from $212M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new COGT positions and 6 closed out — a net gain of 4 holders — while 14 added to existing stakes and 12 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $989K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.15M sold.
- 48 institutional investors held Cogent Biosciences (COGT) as of Q3 2018, up from 44 in Q2 2018.
- Funds reported $158M of Cogent Biosciences stock for Q3 2018, down 26% quarter-over-quarter.
- 10 funds opened new Cogent Biosciences positions in Q3 2018 and 6 closed out, a net change of +4 holders.
- The largest Cogent Biosciences buyer in Q3 2018 was Renaissance Technologies, an estimated $989K added.
- The largest Cogent Biosciences seller in Q3 2018 was Point72 Asset Management, an estimated $2.15M sold.
Based on aggregated 13F filings for Q3 2018.